

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
11 November 2004 (11.11.2004)

PCT

(10) International Publication Number
WO 2004/097006 A1

(51) International Patent Classification⁷:
C12P 1/00, C12M 3/00, C12N 5/00

C12N 1/02,

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(21) International Application Number:
PCT/NL2004/000300

(22) International Filing Date: 3 May 2004 (03.05.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
03101205.7 1 May 2003 (01.05.2003) EP

(71) Applicant (for all designated States except US): DSM IP ASSETS B.V. [NL/NL]; Het Overloon 1, NL-6411 TE Heerlen (NL).

(72) Inventor; and
(75) Inventor/Applicant (for US only): POL, VAN DER, Leonardus, Adolfus [NL/NL]; Adelheidstraat 22, NL-9717 AS Groningen (NL).

(74) Agent: HABETS, Winand, Johannes, Petrus; Intellectual Property, P.O. Box 9, NL-6160 MA Geleen (NL).

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



A1

WO 2004/097006 A1

(54) Title: PROCESS FOR THE PRODUCTION OF BIOLOGICAL SUBSTANCES BY PERfusion CULTURING OF SUSPENDED ANIMAL CELLS

(57) Abstract: The invention relates to a process for the production of a biological substance by perfusion culturing of suspended animal cells in a serum free cell culture medium, wherein the biological substance is separated from the cells by filtration, characterized in that at least 0.001w/w% nonionic surfactant is present in the cell culture medium. It has been found that the presence of nonionic surfactant in the cell culture medium improves the filter performance.

JC20 Rec'd PCT/PTO 26 OCT 2005

PROCESS FOR THE PRODUCTION OF BIOLOGICAL SUBSTANCES BY
PERFUSION CULTURING OF SUSPENDED ANIMAL CELLS

5

The invention relates to a process for the production of biological substances by perfusion culturing of suspended animal cells in a serum free cell culture medium, wherein the biological substance is separated from the cells by filtration.

Such processes are known in the art, for instance a review on 10 perfusion culturing was written by Tokashiki *et al.* 1993. *Cytotechnology*, vol. 13: 149-159. In perfusion culturing, wherein the biological substance is separated from the cells by filtration, it is preferred that the filtration is such that 1) the cells are retained by the filter, while 2) liquid comprising the biological substance passes through the filter. A measure for how well a filter performs these two tasks is the product of the mean total 15 cell concentration in the cell culture and the total volume that passes the filter (filter performance). The filter performance is proportional to the yield of the biological substance.

A disadvantage of perfusion culturing, wherein the biological substance is separated from the cells by filtration, however, is that filter clogging occurs 20 during the process. Filter clogging limits the total amount of volume that can pass the filter, thereby limiting filter performance and thereby also limiting the yield of the biological substance.

It is the object of the invention to provide a process for the production 25 of biological substances by perfusion culturing of suspended animal cells in a serum free cell culture medium, wherein the biological substance is separated from the cells by filtration, wherein filter clogging is diminished (i.e. the filter performance is increased).


This object is achieved by the invention by the presence of an amount of non-ionic surfactant of at least 0.001 w/w% in the cell culture medium.

30 The use of non-ionic surfactants in a serum-free cell culture medium for mammalian cells is known from US 5,372,943, however, in US 5,372,943, the use is directed to the provision of essential lipids in a bioavailable form in the cell culture medium. The applicant has surprisingly found that the use of non-ionic surfactants in a serum-free culture medium for mammalian cells also diminishes filter clogging.

35 In principle, the upper limit of the amount of non-ionic surfactant to be used in the serum-free culture medium is not very critical. It may, however, for example be limited by the toxicity level and/or the solubility of the non-ionic surfactant. The

upper limit further may depend on the process conditions and can easily be determined by the person skilled in the art. Usually, the upper limit of the amount of non-ionic surfactant present in the cell culture medium is 1 w/w %.

- In the process of the invention, the non-ionic surfactant is preferably
- 5 a fatty acid ester, for instance a fatty acid ester of glycerol or of diglycerol or a polyoxyalkylene sorbitan fatty acid ester represented by formula 1,



- wherein R^1 , R^2 , R^3 and R^4 each independently represent H or a fatty acid restgroup; i.e.
- 10 the remains of a condensation of a fatty acid and an alcohol, provided that at least one of R^1 through R^4 is a fatty acid restgroup, wherein A represents an ethylene or propylene group and n, o, p and q each independently represent values from 0 to 100, wherein preferably the sum of n, o, p, and q is from 50 to 300.

- Preferably the fatty acid restgroup contains 10-20 C-atoms.
- 15 Examples of fatty acids include decanoic acid, lauric acid, palmitic acid, stearic acid, arachidic acid, tall oil acids etc.

- Examples of commercially available compounds of formula 1 include TweenTM-compounds, e.g. TweenTM-80, TweenTM-21, TweenTM-40, TweenTM-60, TweenTM-20, TweenTM-61, TweenTM-65, TweenTM-81, TweenTM-85. Of course, it is also
- 20 possible to use a combination of different non-ionic surfactants in the process of the invention.

- The fatty acid esters are especially advantageous in the process of the invention, since the presence of small amounts of these esters does not present an obstacle for use of the biological substance in a medical application.
- 25 Preferably, the amount of the nonionic surfactant in the cell culture medium is at least 0.005, more preferably at least 0.01, most preferably at least 0.02 w/w%.

- The animal cells that can be used in the process of the present invention are for example mammalian cells, for example CHO (Chinese Hamster Ovary) cells, hybridomas, BHK (Baby Hamster Kidney) cells, myeloma cells and

human cells, for example HEK-293 cells and human lymphoblastoid cells.

The filtration can in principle be performed with all filters suitable for the retention of cells. Examples of such filters are static filters, for example hollow fiber filter or tangential flow filters or rotating filters, for example spinfilters. Preferably, if the 5 biological substance is a biopharmaceutical product, an internal filter is used as the use of an external filter requires additional validation for the approval of the production process of the biopharmaceutical product according to GMP (good manufacturing practice) standards. An example of a suitable internal filter is an internal spinfilter.

The most suitable mesh size of a filter depends on the cell diameter 10 of the cells to be retained and can easily be determined by a person skilled in the art. The mesh size is preferably chosen such that the size of the pores in the mesh is close to the diameter of the suspended cells, ensuring a high retention of cells while cell debris can pass the filter. Preferably, the meshsize is between 500x3000-50x300.

The invention can in principle be used in any type of cell culture 15 medium suitable for the culturing of animal cells. Guidelines for choosing a cell culture medium and cell culture conditions are well known and are for instance provided in Chapter 8 and 9 of Freshney, R. I. Culture of animal cells (a manual of basic techniques), 4th edition 2000, Wiley-Liss and in Doyle, A., Griffiths, J. B., Newell, D. G. Cell & Tissue culture: Laboratory Procedures 1993, John Wiley & Sons.

Serum free media are preferred to media containing a serum source 20 in the production of biopharmaceutical products as serum source media are frequently contaminated with viruses, present the risk of prionic infections, and can create a major obstacle in the downstream processing of the biopharmaceutical product (i.e. the further purification of the biopharmaceutical product from the cell culture medium). Since compounds from a mammalian source also present an infection risk, preferably, 25 the cell culture medium is not only serum-free, but also mammalian source free. More preferably the cell culture medium is not only mammalian source-free, but also animal source free.

The pH, temperature, dissolved oxygen concentration and osmolarity 30 of the cell culture medium are in principle not critical and depend on the type of cell chosen. Preferably, the pH, temperature, dissolved oxygen concentration and osmolarity are chosen such that it is optimal for the growth and productivity of the cells. The person skilled in the art knows how to find the optimal pH, temperature, dissolved oxygen concentration and osmolarity for the perfusion culturing. Usually, the optimal 35 pH is between 6.6 and 7.6, the optimal temperature between 30 and 39°C, the optimal osmolarity between 260 and 400mOsm and the dissolved oxygen concentration in the

cell culture medium between 5 and 95% of air saturation.

The biological substances that can suitably be produced in the perfusion culturing by the animal cell are in principle all biological substances that can be produced by an animal cell, for example therapeutic and diagnostic

- 5 proteins, for example monoclonal antibodies, growth factors and enzymes, DNAs, which for example might be used in gene therapy, vaccines, hormones etc. Preferably, the process according to the invention is used for the production of a biopharmaceutical product, which is a biological substance with a medical application. Examples of biopharmaceutical products are as follows (with
- 10 examples of brand names of the corresponding biopharmaceutical product between brackets): Tenecteplase (TN KaseTM), (recombinant) antihemophilic factor (ReFactoTM), lymphoblastoid Interferon α-n1 (WellferonTM), (recombinant) Coagulation factor (NovoSevenTM), Etanercept, (EnbrelTM), Trastuzumab (HerceptinTM), Infliximab (RemicadeTM), Basiliximab (SimulectTM), Daclizumab (ZenapazTM), (recombinant) Coagulation factor IX (BenefixTM), erythropoietin alpha (Epogen®), G-CSF (Neupogen®Filgrastim), Interferon alpha-2b (Infergen®), recombinant insulin (Humulin®), Interferon beta 1a (Avonex®), Factor VIII (KoGENate®), Glucocerebrosidase (CerezymeTM), Interferon beta 1b (Betaseron®), TNF alpha receptor (Enbrel®), Follicle stimulating hormone
- 15 (Gonal-F®), Mab abcixmab (Synagis®, ReoPro®), Mab ritiximab (Rituxan®), tissue plasminogen activator (Activase ®, Actilyase®), human growth hormone (Protropin®, Norditropin®, GenoTropinTM). Examples of DNAs with a possible medical application are gene therapeutic plasmid DNAs. Some gene therapeutic DNAs are presently tested in clinical trials for their medical application. Examples
- 20 of vaccines are live, oral, tetravalent Rotavirus vaccine (RotaShieldTM), rabies vaccine (RanAvertTM), Hepatitis B vaccine (RECOMBIVAX HB®, Engerix®) and inactivated hepatitis A vaccine (VAQTATM).
- 25
- 30
- 35

The biological substance, which was passed through the filter can be further purified in so-called downstream processing. Downstream processing usually comprises several purification steps in varying combinations and order. Examples of purification steps in the downstream processing are separation steps (e.g. by affinity chromatography and/or ion exchange chromatography), steps for the concentration of the biological substance (e.g. by ultrafiltration or diafiltration), steps to exchange buffers and/or steps to remove or inactivate viruses (e.g. by virusfiltration, pH shift or solvent detergent treatment).

The invention will be elucidated by way of the following example, without, however, being limited thereto.

Example I

5 PFU-83 hybridoma cells are rat/mouse hetero hybridoma cells producing a rat IgG directed against corticotropin releasing factor (J. W. A. M. van Oers et al. 1989, Endocrinology, 124, pp1239-1246). PFU-83 hybridoma cells were grown on minimal mammalian source free medium at 37°C. The minimal mammalian source free medium used was 3:1 DMEM/Ham's F12 medium, containing ascorbic acid (5 mg/l),
10 recombinant human insulin (5 mg/l), glutathion (1 mg/l), Pluronic™ F68 (500 mg/l), selenium in the form of Na₂SeO₃ (15 µg/l), sodium bicarbonate (3 g/l), ethanolamine (7 µl/l), supplemented with glutamin (final concentration 584.5 mg/l), Na-pyruvate (final concentration 110 mg/l) and transferrin (5 mg/l) with an osmolality of 320 mOsm. The pH was set at 7.0 and the dissolved oxygen concentration was set at 30% air
15 saturation. The culture was performed in a 7 l Applikon fermentor running at 4 l working volume using a spin filter with a mesh size of 325 x 2300 in the presence of different concentrations of Tween®-80 (0, 15 mg/l and 50 mg/l; corresponding to approximately 0; 0.015; and 0.050 w/w%). A viable cell concentration of approximately 5*10⁶ was reached after 4 to 5 days.


20 All different runs had a cell retention of 100%. The time until complete clogging of the filter (the point when the spinfilter flooded) was observed and the spin filter performance was calculated. Spin filter performance is defined as the product of the total volume that passed the spinfilter and the mean total cell concentration in the fermentor. Cell concentrations in the fermentor were determined by counting the total
25 amount of viable and dead cells in cell culture samples taken during the run of the fermentor under a light microscope using a Fuchs-Rosenthal haemacytometer and trypan-blue exclusion for staining of dead cells. The results of this experiment are shown in Table 1 below. From Table 1 it can be seen that the time until clogging, as well as the spin filter performance, is increased with the addition of Tween®-80.

Table 1

[Tween®-80] (mg/l)	Time until complete clogging (days)	Total volume that passed the spinfilter (l)	Mean total cell concentration ($\times 10^9/l$)	Spin filter performance (total cell load)
0	7	14	3.77	53
15	9	25	4.97	127
50	29	99	4.68	463

CLAIMS

1. Process for the production of a biological substance by perfusion culturing of suspended animal cells in a serum free cell culture medium, wherein the 5 biological substance is separated from the cells by filtration, characterized in that at least 0.001 w/w% of polyoxyalkylene sorbitan fatty acid ester represented by formula 1,



- 10 wherein R¹, R², R³ and R⁴ each independently represent H or a fatty acid restgroup, i.e. the remains of a condensation of a fatty acid and an alcohol, provided that at least one of R¹ through R⁴ is a fatty acid restgroup, wherein A represents an ethylene or propylene group and n, o, p and q each independently represent values from 0 to 100, is present in the cell culture 15 medium.
2. Process according to claim 1, characterized in that in formula 1, the sum of n, o, p, and q is from 50 to 300.
3. Process according to claim 1 or claim 2, characterized in that at least 0.01 w/w% of the compound of formula 1 is present in the cell culture medium.
- 20 4. Process according to any of claims 1-3, characterized in that the animal cells are mammalian cells.
5. Process according to any of claims 1-4, characterized in that the compound of formula 1 is a TweenTM compound.
6. Process according to any of claims 1-5, characterized in that the filtration is 25 performed with an internal filter.
7. Process according to claim 6, characterized in that the internal filter is a spinfilter.
8. Process according to any of claims 1-7, characterized in that the biological substance is a biopharmaceutical product.

9. Process according to claim 8, characterized in that the serum free cell culture medium is also a mammalian source free medium.
10. Process according to any of claims 1-9, characterized in that the biological substance is further purified by downstream processing.